- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
1 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
TLX | AU$26.49 | 6.0% | 137.6% | AU$8.7b | AU$24.77 | PE180.3x | E33.1% | n/a | ||
TRJ New | AU$0.95 | -5.0% | -15.9% | AU$147.0m | AU$1.45 | PS0.9x | E98.8% | n/a |
Page 1 of 1